Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats

Behavioural Brain Research

Volumn 197, Issue 1, 2009, Pages 90-96

  Valastro, Barbara ^a   Dekundy, Andrzej ^a   Danysz, Wojciech ^a   Quack, Guenter ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Abnormal involuntary movements; Basal ganglia; Energy deficit; Levodopa; Parkinson's disease; Striatum

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE PHOSPHATE; LACTIC ACID; LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN; PRODYNORPHIN; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIET SUPPLEMENTATION; DYSKINESIA; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROPHYLAXIS; RAT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CREATINE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; ENERGY METABOLISM; ENKEPHALINS; FEMALE; LEVODOPA; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHOCREATINE; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 57649217889     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.08.004     Document Type: Article

References (37)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 (1999) 461-474
2. Andersson M., Konradi C., and Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21 (2001) 9930-9943
3. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8 (2001) 479-491
4. Andreassen O.A., Jenkins B.G., Dedeoglu A., Ferrante K.L., Bogdanov M.B., Kaddurah-Daouk R., et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 77 (2001) 383-390
5. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53 Suppl. 3 (2003) S39-S47 [discussion S47-38]
6. Bergmeyer H.U. Methods of enzymatic analysis (1985), VCH Verlagsgesellschaft, Weinheim, Germany
7. Bemben M.G., and Lamont H.S. Creatine supplementation and exercise performance: recent findings. Sports Med 35 (2005) 107-125
8. Bowling A.C., and Beal M.F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56 (1995) 1151-1171
9. Brustovetsky N., Brustovetsky T., and Dubinsky J.M. On the mechanisms of neuroprotection by creatine and phosphocreatine. J Neurochem 76 (2001) 425-434
10. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96 (2006) 1718-1727
11. Cenci M.A., Lee C.S., and Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
12. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
13. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (2002) 1592-1599
14. Ganesan V., Johnson A., Connelly A., Eckhardt S., and Surtees R.A. Guanidinoacetate methyltransferase deficiency: new clinical features. Pediatr Neurol 17 (1997) 155-157
15. Harris R.C., Soderlund K., and Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci (Lond) 83 (1992) 367-374
16. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151 (1998) 334-342
17. Hespel P., Eijnde B.O., Derave W., and Richter E.A. Creatine supplementation: exploring the role of the creatine kinase/phosphocreatine system in human muscle. Can J Appl Physiol 26 Suppl. (2001) S79-S102
18. Juhn M.S., and Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 8 (1998) 286-297
19. Klivenyi P., Calingasan N.Y., Starkov A., Stavrovskaya I.G., Kristal B.S., Yang L., et al. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 15 (2004) 610-617
20. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5 (1999) 347-350
21. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17 (2004) 219-236
22. Leuzzi V., Bianchi M.C., Tosetti M., Carducci C., Cerquiglini C.A., Cioni G., et al. Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation). Neurology 55 (2000) 1407-1409
23. Lundblad M., Picconi B., Lindgren H., and Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16 (2004) 110-123
24. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157 (1999) 142-149
25. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18 (1998) 156-163
26. Morissette M., Dridi M., Calon F., Tahar A.H., Meltzer L.T., Bedard P.J., et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 21 (2006) 9-17
27. Ohtsuki S., Tachikawa M., Takanaga H., Shimizu H., Watanabe M., Hosova K., et al. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab 22 (2002) 1327-1335
28. Schulze A. Creatine deficiency syndromes. Mol Cell Biochem 244 (2003) 143-150
29. Sgambato-Faure V., Buggia V., Gilbert F., Levesque D., Benabid A.L., and Berger F. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64 (2005) 936-947
30. Stefanova N., Lundblad M., Tison F., Poewe W., Cenci M.A., and Wenning G.K. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 15 (2004) 630-639
31. Tel B.C., Zeng B.Y., Cannizzaro C., Pearce R.K., Rose S., and Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115 (2002) 1047-1058
32. Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., et al. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J Neurochem 102 (2007) 1393-1409
33. Westin J.E., Andersson M., Lundblad M., and Cenci M.A. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 1171-1176
34. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10 (2002) 165-186
35. Zhu S., Li M., Figueroa B.E., Liu A., Stavrovskaya I.G., Pasinelli P., et al. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci 24 (2004) 5909-5912
36. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 5 (2000) 777-787
37. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15 (2002) 120-132